tetano
Editor, Senior Moderator
CEN Case Rep
. 2020 Jun 20;1-4.
doi: 10.1007/s13730-020-00496-4. Online ahead of print.
Fatal SARS-CoV-2 Infection in a Renal Transplant Recipient
Ahmet Burak Dirim[SUP] 1 [/SUP], Erol Demir[SUP] 2 [/SUP], Ali Riza Ucar[SUP] 2 [/SUP], Nurana Garayeva[SUP] 2 [/SUP], Seda Safak[SUP] 2 [/SUP], Ozgur Akin Oto[SUP] 2 [/SUP], Halil Yazici[SUP] 2 [/SUP], Alpay Medet Alibeyoglu[SUP] 3 [/SUP], Gunseli Orhun[SUP] 4 [/SUP], Arif Atahan Cagatay[SUP] 5 [/SUP], Aydin Turkmen[SUP] 2 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) caused a pandemic that first discovered in Wuhan, China. While 10% of the patients have asymptomatic infection, 15-20% have lung involvement, 5-10% have multiple organ failure, and macrophage activation syndrome. Chronic respiratory diseases, diabetes mellitus, hypertension, and cancer are risk factors for mortality. Prognosis or optimal treatment strategy for renal transplant recipients in SARS-CoV-2 infection is still unknown. Besides fatal cases, there were also milder case reports. In addition, COVID-19 treatment and the maintenance immunosuppression strategy is still under debate. Antiviral therapies and drug interactions are special topics for these patients. To the best of our knowledge, favipiravir and anti-cytokine treatments have not been previously reported in a kidney transplant recipient with SARS-CoV-2 infection before. We report a case of SARS-CoV-2 infection in a kidney transplant recipient with fatal outcomes.
. 2020 Jun 20;1-4.
doi: 10.1007/s13730-020-00496-4. Online ahead of print.
Fatal SARS-CoV-2 Infection in a Renal Transplant Recipient
Ahmet Burak Dirim[SUP] 1 [/SUP], Erol Demir[SUP] 2 [/SUP], Ali Riza Ucar[SUP] 2 [/SUP], Nurana Garayeva[SUP] 2 [/SUP], Seda Safak[SUP] 2 [/SUP], Ozgur Akin Oto[SUP] 2 [/SUP], Halil Yazici[SUP] 2 [/SUP], Alpay Medet Alibeyoglu[SUP] 3 [/SUP], Gunseli Orhun[SUP] 4 [/SUP], Arif Atahan Cagatay[SUP] 5 [/SUP], Aydin Turkmen[SUP] 2 [/SUP]
Affiliations
- PMID: 32564306
- PMCID: PMC7305930
- DOI: 10.1007/s13730-020-00496-4
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) caused a pandemic that first discovered in Wuhan, China. While 10% of the patients have asymptomatic infection, 15-20% have lung involvement, 5-10% have multiple organ failure, and macrophage activation syndrome. Chronic respiratory diseases, diabetes mellitus, hypertension, and cancer are risk factors for mortality. Prognosis or optimal treatment strategy for renal transplant recipients in SARS-CoV-2 infection is still unknown. Besides fatal cases, there were also milder case reports. In addition, COVID-19 treatment and the maintenance immunosuppression strategy is still under debate. Antiviral therapies and drug interactions are special topics for these patients. To the best of our knowledge, favipiravir and anti-cytokine treatments have not been previously reported in a kidney transplant recipient with SARS-CoV-2 infection before. We report a case of SARS-CoV-2 infection in a kidney transplant recipient with fatal outcomes.